- Home
- BAFN vs INMB Comparison
BAFN vs INMB Comparison
Compare BAFN & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- INMB
- Stock Information
- Founded
- BAFN 1999
- INMB 2015
- Country
- BAFN United States
- INMB United States
- Employees
- BAFN N/A
- INMB N/A
- Industry
- BAFN Savings Institutions
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- BAFN Finance
- INMB Health Care
- Exchange
- BAFN Nasdaq
- INMB Nasdaq
- Market Cap
- BAFN 63.2M
- INMB 68.9M
- IPO Year
- BAFN N/A
- INMB 2019
- Fundamental
- Price
- BAFN $14.49
- INMB $2.27
- Analyst Decision
- BAFN
- INMB Buy
- Analyst Count
- BAFN 0
- INMB 4
- Target Price
- BAFN N/A
- INMB $9.53
- AVG Volume (30 Days)
- BAFN 14.7K
- INMB 7.1M
- Earning Date
- BAFN 07-29-2025
- INMB 07-31-2025
- Dividend Yield
- BAFN 2.23%
- INMB N/A
- EPS Growth
- BAFN 116.26
- INMB N/A
- EPS
- BAFN 2.37
- INMB N/A
- Revenue
- BAFN $80,167,000.00
- INMB $50,000.00
- Revenue This Year
- BAFN N/A
- INMB $203.60
- Revenue Next Year
- BAFN N/A
- INMB $13,122.47
- P/E Ratio
- BAFN $6.01
- INMB N/A
- Revenue Growth
- BAFN 2.60
- INMB N/A
- 52 Week Low
- BAFN $11.98
- INMB $1.89
- 52 Week High
- BAFN $19.75
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- BAFN 45.01
- INMB 29.80
- Support Level
- BAFN $14.26
- INMB $2.04
- Resistance Level
- BAFN $15.24
- INMB $2.36
- Average True Range (ATR)
- BAFN 0.58
- INMB 0.24
- MACD
- BAFN 0.01
- INMB 0.04
- Stochastic Oscillator
- BAFN 25.86
- INMB 45.51
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.